| Elementary studies on elevated steroidogenic factor-1 expression in aldosterone-producing adenoma. | |
| | |
MedLine Citation:
|
PMID: 20875752 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVES: The expression of steroidogenic factor-1 (SF-1) was elevated in adrenal aldosterone-producing adenoma (APA). The influence of SF-1 on adrenal tumorigenesis by adrenocortical cell line H295R cells was investigated. MATERIALS AND METHODS: Real-time PCR and Western blotting were used to detect SF-1 expression in 16 APA samples and 12 normal adrenal samples. Specific SF-1-shRNA plasmid was transfected into H295R cells to inhibit SF-1 expression. Western blotting and real-time PCR were used to verify the effects of RNAi on SF-1 inhibition. Subsequently, WST-1 and cell count were applied to evaluate cell proliferation at different SF-1 levels. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was used to measure cell apoptosis, and proliferation marker Ki-67 was studied by immunohistochemistry. RESULTS: Compared with normal adrenal samples, SF-1 mRNA and protein levels in APA samples were significantly higher. It was 10.48:1 at SF-1 mRNA and 0.87 ± 0.05 vs. 0.39 ± 0.07 at protein levels, respectively (P < 0.01). A decreased SF-1 significantly inhibited cell proliferation in the experimental and control cells. These results were supported by weaker Ki-67 staining in SF-1-inhibited cells [(36.9% ± 4.17%) vs. (58.48% ± 7.16%) (P < 0.01)]. Moreover, SF-1 inhibition induced a 2.7-fold increase in the percentage of apoptotic H295R cells (P < 0.01). CONCLUSIONS: Elevated SF-1 may play an important role in APA formation and primary aldosteronism. SF-1 acts as an oncogenic factor, and its inhibition provides new insight into the understanding and treatment of related adrenal diseases. |
| | |
Authors:
|
Dongliang Hu; Jinzhi Ouyang; Zhun Wu; Taoping Shi; Baojun Wang; Xin Ma; Hongzhao Li; Shaogang Wang; Xu Zhang |
Publication Detail:
|
Type: Journal Article Date: 2010-09-26 |
Journal Detail:
|
Title: Urologic oncology Volume: 30 ISSN: 1873-2496 ISO Abbreviation: Urol. Oncol. Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-06-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9805460 Medline TA: Urol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 457-62 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
Next Document: Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous re...